How to Cite
1.
OPROMOLLA D. Adverse reactions to rifampicin with special reference to acute renal failure. Hansen. Int. [Internet]. 1992 Nov. 30 [cited 2024 Dec. 23];17(1/2):1-4. Available from: https://periodicos.saude.sp.gov.br/hansenologia/article/view/35232
Abstract
.
References
1. DEDHIA, N.M.; ALMEIDA, A.F.; KHANNA, V.B.; MITTAL, B.V. &ACHARYA, V.M. Acute renal failure -acomplication of new multidrug regimenfortreatmentofleposy.Int J. Lepr., 54(3): 380-382,1986.
2. GIRLING, D.J. Adverse reactions to rifampicin in antituberculosis regimens. Journal ofAntimicrobial Chemotherapy3115-132,1977.
3. GUPTA, A.; SAKHUJA, V.; GUPTA, K.L &GHUGH, K.S. Intravascularhemolysis and acute renal failure following intermittent rifampin therapy. lnt J. Lepr. 60(2):185-188,1992.
4. KAR, H.K.; ROY, R.G. Reversible acute renal failure due to monthly administration of rifampicin in a leprosy patient. Int J. Lepr. 56(4): 835-839,1984.
5. MINISTÉRIO DA SAÚDE. FUNDAÇÃO NACIONAL DA SAÚDE. Avaliação independente do programa nacional de controle e eliminação da hanseníase. Relatório final, Brasília, novembro de 1992, 294p.
6. NOORDEEN, S.K. Worldwide implementation of WHO/MDTand experiences gained. In: Conference on Chemotherapy of Leprosy,
Greenville, 6-8 April. Paper. Geneva, World Health Organization, 1992.
7. PALANDE, D.D. Lapolychimiothérapieentrainetyelle descomplications? /Editorial/. Acta Leprolágica 7(2):105-107,1990.
8. PAPAIORDANOU, P.M. de O.; BRANCHINI, M.L.M.; GONÇALVES JÚNIOR, F.L.; AOKI, F.H.; BOCCATO, R.S.B.S.; RAMOS, M. de C.;
PEDRO, R. de V. - Efeito adverso do uso intermitente de Rifampicina para tratamento de hanseníase. Rev. inst. med. trop. São Paulo, 30(5): 383-386, 1988.
2. GIRLING, D.J. Adverse reactions to rifampicin in antituberculosis regimens. Journal ofAntimicrobial Chemotherapy3115-132,1977.
3. GUPTA, A.; SAKHUJA, V.; GUPTA, K.L &GHUGH, K.S. Intravascularhemolysis and acute renal failure following intermittent rifampin therapy. lnt J. Lepr. 60(2):185-188,1992.
4. KAR, H.K.; ROY, R.G. Reversible acute renal failure due to monthly administration of rifampicin in a leprosy patient. Int J. Lepr. 56(4): 835-839,1984.
5. MINISTÉRIO DA SAÚDE. FUNDAÇÃO NACIONAL DA SAÚDE. Avaliação independente do programa nacional de controle e eliminação da hanseníase. Relatório final, Brasília, novembro de 1992, 294p.
6. NOORDEEN, S.K. Worldwide implementation of WHO/MDTand experiences gained. In: Conference on Chemotherapy of Leprosy,
Greenville, 6-8 April. Paper. Geneva, World Health Organization, 1992.
7. PALANDE, D.D. Lapolychimiothérapieentrainetyelle descomplications? /Editorial/. Acta Leprolágica 7(2):105-107,1990.
8. PAPAIORDANOU, P.M. de O.; BRANCHINI, M.L.M.; GONÇALVES JÚNIOR, F.L.; AOKI, F.H.; BOCCATO, R.S.B.S.; RAMOS, M. de C.;
PEDRO, R. de V. - Efeito adverso do uso intermitente de Rifampicina para tratamento de hanseníase. Rev. inst. med. trop. São Paulo, 30(5): 383-386, 1988.
This journal is licensed under a Creative Commons Attribution 4.0 International License.
Downloads
Download data is not yet available.
